Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Total Current Assets
All assets expected to be converted to cash or used up within one year.
Turn Therapeutics Inc.NASDAQ: TTRX
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets of $11.45M in Q1 FY2026
Q1 FY2026 total current assets was $11.45M.
Context
- Total current assets amounted to 61.4% of total assets at the end of Q1 FY2026.
- Total current assets increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 5.2M USD
- Year-over-year change
- +373.3%
- 2-year CAGR
- +107.9%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.2M | +373.3% |
| FY2024 | 2024-12-31 | 1.1M | -8.6% |
| FY2023 | 2023-12-31 | 1.2M | — |
Total Current Assets vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 total current assets of $11.45M is the 7th highest of the 9 companies compared; the peer median is $51.21M.
- Total current assets amounts to 61.4% of total assets for TTRX, versus a peer median of 99.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $181.59M | -28.9% | -22.6% | 66.7% | |
| Mar 2026 | $172.18M | +82.8% | +94.8% | 99.3% | |
| Mar 2026 | $95.28M | +311.8% | -14.5% | 51.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $66.6M | +39.0% | +0.7% | 99.7% |
| Mar 2026 | $35.81M | +56.6% | +0.2% | 99.1% | |
| Apr 2026 | $14.69M | -12.4% | -19.3% | 98.8% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $11.45M | — | — | 61.4% |
| Mar 2026 | $10.51M | +282.0% | — | 100.0% | |
| Mar 2026 | $6.98M | -51.3% | -32.1% | 23.5% | |
| Peer median (excluding TTRX) | $51.21M | +47.8% | -14.5% | 99.0% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.